CN101679407A - 新的苯并吡喃-2-酮衍生物 - Google Patents
新的苯并吡喃-2-酮衍生物 Download PDFInfo
- Publication number
- CN101679407A CN101679407A CN200880015390A CN200880015390A CN101679407A CN 101679407 A CN101679407 A CN 101679407A CN 200880015390 A CN200880015390 A CN 200880015390A CN 200880015390 A CN200880015390 A CN 200880015390A CN 101679407 A CN101679407 A CN 101679407A
- Authority
- CN
- China
- Prior art keywords
- chromen
- group
- compound
- alkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 15
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- XWUYAOGTCSHHTQ-UHFFFAOYSA-N 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid Chemical compound C1C(O)CC2CCC1N2C(O)=O XWUYAOGTCSHHTQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000007858 starting material Substances 0.000 abstract 1
- 239000002585 base Substances 0.000 description 38
- 125000005843 halogen group Chemical group 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 8
- -1 isobutyl- Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- SQUPBVCRSYNHPF-UHFFFAOYSA-N CCCCCC([O])CC Chemical compound CCCCCC([O])CC SQUPBVCRSYNHPF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical group CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- AFVDZBIIBXWASR-AATRIKPKSA-N (E)-1,3,5-hexatriene Chemical compound C=C\C=C\C=C AFVDZBIIBXWASR-AATRIKPKSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OXCUXUWBKSSTCK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C2CCC1CC([O])C2 Chemical compound CC(C)(C)OC(=O)N1C2CCC1CC([O])C2 OXCUXUWBKSSTCK-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- OWIHWZAVHVREEJ-UHFFFAOYSA-N chromen-2-one;hydrochloride Chemical compound Cl.C1=CC=C2OC(=O)C=CC2=C1 OWIHWZAVHVREEJ-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- AKOJBFZCIRFXBA-UHFFFAOYSA-N hexa-1,3-diyne Chemical compound CCC#CC#C AKOJBFZCIRFXBA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001561 neurotransmitter reuptake Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及可用作药物合成原料的新的苯并吡喃-2-酮衍生物。在其它方面中,本发明涉及一种制备本发明的苯并吡喃-2-酮衍生物的方法。
Description
技术领域
本发明涉及可用作药物合成原料的新的苯并吡喃-2-酮衍生物。
在其它方面中,本发明涉及一种制备本发明的苯并吡喃-2-酮衍生物的方法。
背景技术
WO 2006/035034公开了一组可用作单胺神经递质再摄取抑制剂的苯并吡喃-2-酮衍生物。在该文献中,(8-H-8-氮杂-二环[3.2.1]辛-3-基氧基)-苯并吡喃-2-酮-基衍生物是通过将相应的8-甲基-或8-叔丁氧基羰基-8-氮杂-二环[3.2.1]辛-3-基氧基-苯并吡喃-2-酮衍生物脱保护而合成的。
但是,当合成大量的药物化合物时,所述合成需要与之相称,例如其可用于制备无需色谱纯化的结晶中间体和终产物。
此外,从纯度和再现性方面来看所述方法应适用于特定的要求。
因此,考虑到该组化合物的规模化而发明了更适合的合成方法。
发明概述
在其第一方面中,本发明提供式I化合物:
其任何立体异构体或其立体异构体的任何混合物,或其加成盐,其中Q如下述定义。
在其第二方面中,本发明提供一种制备式I化合物的方法。
对本领域技术人员而言,通过下列详细描述和实施例将使本发明的其它方面显而易见。
发明详述
苯并吡喃-2-酮衍生物
在其第一方面中,本发明提供式I化合物:
其任何立体异构体或其立体异构体的任何混合物,
或其加成盐,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基任选地被一个或多个独立地选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。
在式I化合物的进一步的实施方案中,Q代表苯并吡喃-2-酮-基。在式I化合物的特定实施方案中,Q代表苯并吡喃-2-酮-7-基。在式I化合物的进一步的实施方案中,Q代表苯并吡喃-2-酮-6-基。在式I化合物的再进一步的实施方案中,Q代表苯并吡喃-2-酮-4-基。
在式I化合物的再进一步的实施方案中,Q代表取代的苯并吡喃-2-酮-基。再进一步的实施方案中,苯并吡喃-2-酮-基被选自卤代、氰基和烷基的取代基取代。在式I化合物的特定实施方案中,Q代表取代的苯并吡喃-2-酮-7-基,例如卤代、氰基或烷基取代的苯并吡喃-2-酮-7-基。在式I化合物的进一步的实施方案中,Q代表取代的苯并吡喃-2-酮-6-基,例如卤代、氰基或烷基取代的苯并吡喃-2-酮-6-基。在式I化合物的再进一步的实施方案中,Q代表取代的苯并吡喃-2-酮-4-基,例如卤代、氰基或烷基取代的苯并吡喃-2-酮-4-基。
在进一步的实施方案中,Q代表苯并吡喃-2-酮-基,该苯并吡喃-2-酮-基在3-位上被选自下组的取代基取代:卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。在特定的实施方案中,苯并吡喃-2-酮-基在3-位上被选自卤代、氰基和烷基的取代基取代。
在更进一步的特定实施方案中,Q代表3-卤代-苯并吡喃-2-酮-基,例如3-卤代-苯并吡喃-2-酮-6-基或3-卤代-苯并吡喃-2-酮-7-基。在特定的实施方案中,Q代表3-溴-苯并吡喃-2-酮-6-基、3-溴-苯并吡喃-2-酮-7-基、3-氯-苯并吡喃-2-酮-6-或3-氯-苯并吡喃-2-酮-7-基。
在进一步的特定实施方案中,Q代表3-氰基-苯并吡喃-2-酮-基,例如3-氰基-苯并吡喃-2-酮-6-基或3-氰基-苯并吡喃-2-酮-7-基。
在更进一步的实施方案中,Q代表苯并吡喃-2-酮-基,该苯并吡喃-2-酮-基在4-位上被选自下组的取代基取代:卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。在特定的实施方案中,苯并吡喃-2-酮-基在4-位上被选自卤代、氰基和烷基的取代基取代。在进一步的实施方案中,Q代表4-烷基-苯并吡喃-2-酮-基,例如4-甲基-苯并吡喃-2-酮-基,例如4-甲基-苯并吡喃-2-酮-6-基。
在进一步的实施方案中,Q代表苯并吡喃-2-酮-基,该苯并吡喃-2-酮-基在3-和4-位上被独立地选自下组的取代基取代:卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。在特定的实施方案中,苯并吡喃-2-酮-基在3-和4-位上被独立地选自卤代、氰基和烷基的取代基取代。在进一步的特定实施方案中,Q代表烷基-氰基-苯并吡喃-2-酮-基,例如甲基-氰基-苯并吡喃-2-酮-基,例如4-甲基-3-氰基-苯并吡喃-2-酮-基。在特定的实施方案中,Q代表4-甲基-3-氰基-苯并吡喃-2-酮-6-基或4-甲基-3-氰基-苯并吡喃-2-酮-7-基。
在更进一步的实施方案中,Q代表任选取代的苯并吡喃-2-酮-4-基。
在进一步的实施方案中,Q代表任选取代的苯并吡喃-2-酮-6-基。
在更进一步的实施方案中,Q代表任选取代的苯并吡喃-2-酮-7-基。
在特定的实施方案中,本发明的化合物为外型-3-(2-氧代-2H-苯并吡喃-7-基氧基)-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2,2-三氯-乙酯,或其加成盐。
制备方法
在其第二方面中本发明提供一种制备式I化合物、其任何立体异构体或其立体异构体的任何混合物的方法
其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基任选地被一个或多个独立地选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基;
该方法包括:
使3-羟基-8-氮杂-二环[3.2.1]辛烷-8-羧酸乙酯
与羟基-苯并吡喃-2-酮反应,
该羟基-苯并吡喃-2-酮任选地进一步被一个或多个独立地选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。
在其第三方面中本发明提供一种制备式II化合物、其任何立体异构体或其立体异构体的任何混合物的方法
其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基任选地被一个或多个独立地选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基;
该方法包括:
在过渡金属催化剂存在下使式I化合物与酸反应
其中Q如式II中的定义。
在一个实施方案中,所述过渡金属为锌。
本发明的化合物可以通过化学合成中的常规方法,例如工作实施例中描述的那些方法制备。用于本申请中描述的方法的原料是已知的或者可以容易地通过常规方法由可商购获得的化学品制备。
使用常规方法还可以将本发明的一个化合物转化为本发明的另一个化合物。
本文中描述的反应的终产品可以通过常规技术,例如萃取、结晶、蒸馏、色谱等分离。
上述实施方案中的两个或多个的任意组合均被视为在本发明的范围内。
取代基的定义
在本发明的上下文中,卤代代表氟代、氯代、溴代或碘代。
在本发明的上下文中,烷基指单价饱和的、直链或支链烃链。烃链优选含有1-6个碳原子(C1-6-烷基),包括戊基、异戊基、新戊基、叔戊基、己基和异己基。在优选的实施方案中,烷基代表C1-4-烷基,包括丁基、异丁基、仲丁基和叔丁基。在本发明的另一个优选实施方案中,烷基代表C1-3-烷基,其尤其地可以为甲基、乙基、丙基或异丙基。
在本发明的上下文中,烯基指含有一个或多个双键的碳链,包括二烯、三烯和多烯。在优选实施方案中,本发明的烯基包括2-6个碳原子(C2-6-烯基),包括至少一个双键。在最优选的实施方案中,本发明的烯基为乙烯基;1-或2-丙烯基;1-,2-或3-丁烯基或1,3-丁二烯基;1-,2-,3-,4-或5-己烯基或1,3-己二烯基或1,3,5-己三烯基。
在本发明的上下文中,炔基指含有一个或多个三键的碳链,包括二炔、三炔和多炔。在优选的实施方案中,本发明的炔基包括2-6个碳原子(C2-6-炔基),包括至少一个三键。在其最优选的实施方案中,本发明的炔基为乙炔基;1-或2-丙炔基;1-,2-或3-丁炔基,或者1,3-丁二炔基;1-,2-,3-,4-戊炔基,或者1,3-戊二炔基;1-,2-,3-,4-或5-己炔基,或者1,3-己二炔基或1,3,5-己三炔基。
在本发明的上下文中,环烷基指环状烷基,优选含有3-7个碳原子(C3-7-环烷基),包括环丙基、环丁基、环戊基、环己基和环庚基。
烷氧基为O-烷基,其中烷基如上述定义。
环烷氧基意指O-环烷基,其中环烷基如上述定义。
环烷基烷基意指上述环烷基和上述烷基,指的是例如环丙基甲基。
氨基为NH2或NH-烷基或N-(烷基)2,其中烷基如上述定义。
加成盐
本发明的化合物可以提供为适合作为进一步合成的原料的任何形式。适当的形式包括加成盐。
加成盐的例子包括但不限于无毒的无机和有机酸加成盐,例如盐酸盐、氢溴酸盐、硝酸盐、高氯酸盐、磷酸盐、硫酸盐、甲酸盐、乙酸盐、康酸盐(aconate)、抗坏血酸盐、苯磺酸盐、苯甲酸盐、肉桂酸盐、柠檬酸盐、双羟萘酸盐、庚酸盐、富马酸盐、谷氨酸盐、乙醇酸盐、乳酸盐、马来酸盐、丙二酸盐、扁桃酸盐、甲磺酸盐、衍生的萘-2-磺酸、邻苯二甲酸盐、水杨酸盐、山梨酸盐、硬脂酸盐、琥珀酸盐、酒石酸盐、甲苯-对-磺酸盐等。这种盐可以通过所属领域公知和描述的步骤来形成。
其它酸例如草酸被认为不是药学上可接受的,但是其也可以使用。
在本发明的上下文中,含N化合物的“鎓盐”也被视为可接受的加成盐。优选的“鎓盐”包括烷基-鎓盐、环烷基-鎓盐和环烷基烷基-鎓盐。
立体异构体
所属领域那些熟练技术人员应该理解,本发明的化合物可以以不同的立体异构形式存在,包括对映异构体、非对映异构体或顺-反-异构体。
例如,就式I的基团-O-Q中的氮杂二环而言,其尤其地可以为外型或内型。
本发明包括所有这种异构体及其任何混合物,包括外消旋混合物。
可以采用已知的方法和技术将外消旋异构体拆分为光学对映体。分离光学异构化合物(包括光学异构中间体)的一种方式是-在所述化合物为手性酸的情况下-使用光学活性胺,并通过用酸处理而释放非对映异构体、拆分的盐。将外消旋物拆分为光学对映体的另一种方法基于在光学活性基质上进行的色谱法。因此,本发明的外消旋化合物可以,例如通过如D-或L-(酒石酸盐、扁桃酸盐或樟脑磺酸盐)分级结晶拆分为其光学对映体。
还可以使本发明的化合物与光学活性的活化羧酸,例如衍生自(+)或(-)苯基丙氨酸、(+)或(-)苯基甘氨酸、(+)或(-)樟脑酸的羧酸反应形成非对映异构酰胺,或者使本发明的化合物与光学活性的氯甲酸酯等反应形成非对映异构的氨基甲酸酯,从而拆分本发明的化合物。
拆分光学异构体的其它方法是所属领域已知的。这种方法包括Jaques J,Collet A,&Wilen S,“Enantiomers,Racemates,and Resolutions”,John Wiley and Sons,New York(1981)中描述的方法。
光学活性化合物还可以由光学活性原料制备。
标记化合物
本发明的化合物可以使用其标记或非标记形式。在本发明的上下文中,所述标记化合物具有一个或多个被原子质量或质量数不同于天然发现的原子质量或质量数的原子所取代的原子。经标记则可以容易地定量检测所述化合物。
本发明的标记化合物可以在各种诊断方法中用作诊断工具、放射性示踪物或监测试剂,并且用于体内受体成像。
本发明的标记异构体优选含有至少一个作为标记的放射性核素。释放正电子的放射性核素均为可用的候选物。在本发明的上下文中放射性核素优选选自2H(氘)、3H(氚)、13C、14C、131I、125I、123I和18F。
检测本发明的标记异构体的物理方法可以选自正电子发射断层显像法(Position Emission Tomography)(PET)、单光子成像计算机断层显像法(Single Photon Imaging Computed Tomography)(SPECT)、磁共振光谱(MRS)、磁共振成像(MRI)和计算机轴向X-射线断层显像法(Computed Axial X-ray Tomography)(CAT)或其组合。
实施例
参考下列实施例进一步说明本发明,其并不意图以任何方式限制所要求的范围。
制备例
所有涉及空气敏感试剂或中间体的反应均在氮气和无水溶剂中进行。在处理步骤中使用硫酸镁作为干燥剂并减压蒸发溶剂。
实施例1
内型-3-羟基-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2,2-三氯-乙酯
为了除去水实现干燥,使用迪安-斯塔克装置回流内型-8-甲基-8-氮杂-二环[3.2.1]辛-3-醇(托品醇)(140g,991mmol)和甲苯(2L)的混合物。使用机械搅拌经10-15分钟将2,2,2-三氯乙基氯甲酸酯(420g,1983mmol)加入到混合物中。温度升高至35℃,随后沉淀。将混合物机械搅拌4天。混合物变为稠粥状。加水(500ml),随后机械搅拌10min,之后过滤。用石油醚(200ml)和水(200ml)洗涤结晶产物。产率173g(58%)。分离滤液,用水(200ml)洗涤有机相并蒸发至约1L。将有机相放在冰箱中15h,之后过滤。用石油醚(50ml)和水(50ml)洗涤结晶产物。产率75.6g(25%)。将滤液蒸发至一半体积,加入石油醚(250ml),将混合物贮存在冰箱中15h,之后过滤。用石油醚(20ml)和水(20m l)洗涤结晶产物。产率10.6g(4%)。将滤液与氢氧化钠水溶液(50ml,4M)一起搅拌,分离各相,用水洗涤有机相,之后蒸发。向混合物中加入石油醚(200ml),使其在冰箱中放置15h,之后过滤。用石油醚(20ml)和水(20ml)洗涤结晶产物。产率3.2g(1%)。总产率262.4g(87%)。
实施例2
外型-3-(2-氧代-2H-苯并吡喃-7-基氧基)-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2,2-三氯-乙酯
将三苯基膦(269,4g 1027mmol)溶解在二氧己环(1L)中。在冰冷却、低于20℃下经1h将溶解在甲苯中的40%偶氮二甲酸二乙酯(450ml,1027mmol)加入到混合物中。经5min加入内型-3-羟基-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2,2-三氯-乙酯(259g,856mmol)。未发生温度变化。将混合物搅拌30min。经10min逐份加入7-羟基香豆素(153g,942mmol)。温度升高至42℃,室温下搅拌混合物15h。反应混合物变为粥状。加入氢氧化钠水溶液(1L,4M),之后搅拌15min。过滤混合物,用水(500ml)和绝对乙醇(2x200ml)洗涤结晶。产率194.9(51%)。
实施例3
该实施例说明了本发明的化合物用于合成药物化合物的用途。
7-[(3-外型)-8-氮杂-二环[3.2.1]辛-3-基氧基]-苯并吡喃-2-酮盐酸盐
将外型-3-(2-氧代-2H-苯并吡喃-7-基氧基)-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2,2-三氯-乙酯(190g,425mmol)溶解在THF(1L)中。加入水(500ml)和乙酸(250ml)。经2h加入锌粉(69.5g,1063mmol),温度最高升高至35℃。搅拌反应混合物一个周末。反应混合物变为粥状。加入水(500ml)和浓盐酸(100ml,1.2mmol)。室温下搅拌混合物15min,之后搅拌并冰冷却1h。过滤混合物并用冷水(2x200ml)洗涤产物。从水(4L)中重结晶出晶体,包括保温-过滤:分离杂质外型-3-(2-氧代-2H-苯并吡喃-7-基氧基)-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2-二氯-乙酯(18g,43.7mmol)。使产物结晶15h。用水(2x100ml)、乙醇(3x50ml)和乙醚(2x150ml)洗涤结晶。产率73.6(56%)。加入氨水使母液呈碱性,之后过滤。分离游离碱:产率21.3(19%)。最后一步的总产率75%。
Claims (15)
2.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基。
3.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基被选自卤代、氰基和烷基的取代基取代。
4.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基在3-位上被选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。
5.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基在3-位上被选自卤代、氰基和烷基的取代基取代。
6.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基在4-位上被选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。
7.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基在4-位上被选自卤代、氰基和烷基的取代基取代。
8.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基在3-和4-位上被独立地选自下组的取代基取代:
卤代、三氟甲基、三氟甲氧基、氰基、羟基、氨基、硝基、烷氧基、环烷氧基、烷基、环烷基、环烷基烷基、烯基和炔基。
9.权利要求1的化合物,其中Q代表苯并吡喃-2-酮-基,
该苯并吡喃-2-酮-基在3-和4-位上被独立地选自卤代、氰基和烷基的取代基取代。
10.权利要求1-5中任一项的化合物,其中
Q代表任选取代的苯并吡喃-2-酮-4-基。
11.权利要求1-9中任一项的化合物,其中
Q代表任选取代的苯并吡喃-2-酮-6-基。
12.权利要求1-9中任一项的化合物,其中
Q代表任选取代的苯并吡喃-2-酮-7-基。
13.权利要求1的化合物,其为
外型-3-(2-氧代-2H-苯并苯并吡喃-7-基氧基)-8-氮杂-二环[3.2.1]辛烷-8-羧酸2,2,2-三氯-乙酯,
或其药学上可接受的盐。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200700692 | 2007-05-09 | ||
DKPA200700692 | 2007-05-09 | ||
US91718307P | 2007-05-10 | 2007-05-10 | |
US60/917,183 | 2007-05-10 | ||
PCT/EP2008/055683 WO2008138854A1 (en) | 2007-05-09 | 2008-05-08 | Novel chromen-2-one derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101679407A true CN101679407A (zh) | 2010-03-24 |
CN101679407B CN101679407B (zh) | 2012-01-04 |
Family
ID=39651255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800153902A Expired - Fee Related CN101679407B (zh) | 2007-05-09 | 2008-05-08 | 新的苯并吡喃-2-酮衍生物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7994323B2 (zh) |
EP (1) | EP2158200B1 (zh) |
JP (1) | JP2010526122A (zh) |
CN (1) | CN101679407B (zh) |
AR (1) | AR066495A1 (zh) |
AT (1) | ATE516287T1 (zh) |
AU (1) | AU2008250348A1 (zh) |
CA (1) | CA2686891A1 (zh) |
MX (1) | MX2009011987A (zh) |
TW (1) | TW200904815A (zh) |
WO (1) | WO2008138854A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2011143972A (ru) | 2009-05-15 | 2013-06-20 | НьюроСёрч А/С | Производные хромен-2-она и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500739A (ja) * | 1995-10-13 | 2000-01-25 | アグレボ・ユー・ケイ・リミテツド | 複素環式殺菌剤 |
CA2244773C (en) | 1996-02-22 | 2006-01-03 | Neurosearch A/S | Tropane-derivatives, their preparation and use |
US20040106643A1 (en) | 2001-05-23 | 2004-06-03 | Gouliaev Alex Haarh | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
WO2003106452A2 (en) | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
BRPI0411608A (pt) | 2003-06-24 | 2006-08-08 | Neurosearch As | derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo |
US7538233B2 (en) | 2003-09-05 | 2009-05-26 | Aventis Pharmaceuticals Inc. | Coumarins as iNOS inhibitors |
US7696350B2 (en) | 2004-09-30 | 2010-04-13 | Neurosearch A/S | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
MX2007007261A (es) | 2004-12-17 | 2007-08-14 | Neurosearch As | Enantiomeros de 3-heteroaril-8h-8-azabiciclo(3.2.1)oct-2-eno y su uso como inhibidores de la recaptacion del neurotransmisor de monoamina. |
CA2673454A1 (en) | 2006-12-20 | 2008-06-26 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
MX2009006213A (es) | 2006-12-20 | 2010-06-30 | Neurosearch As | Nuevos derivados de cromen-2-ona y su uso como inhibidores de reabsorcion del neurotransmisor monoamina. |
-
2008
- 2008-05-07 TW TW097116757A patent/TW200904815A/zh unknown
- 2008-05-08 CA CA002686891A patent/CA2686891A1/en not_active Abandoned
- 2008-05-08 US US12/599,186 patent/US7994323B2/en not_active Expired - Fee Related
- 2008-05-08 AR ARP080101955A patent/AR066495A1/es unknown
- 2008-05-08 JP JP2010506937A patent/JP2010526122A/ja not_active Abandoned
- 2008-05-08 AU AU2008250348A patent/AU2008250348A1/en not_active Abandoned
- 2008-05-08 WO PCT/EP2008/055683 patent/WO2008138854A1/en active Application Filing
- 2008-05-08 CN CN2008800153902A patent/CN101679407B/zh not_active Expired - Fee Related
- 2008-05-08 AT AT08759467T patent/ATE516287T1/de not_active IP Right Cessation
- 2008-05-08 MX MX2009011987A patent/MX2009011987A/es active IP Right Grant
- 2008-05-08 EP EP08759467A patent/EP2158200B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
AR066495A1 (es) | 2009-08-26 |
CN101679407B (zh) | 2012-01-04 |
ATE516287T1 (de) | 2011-07-15 |
US7994323B2 (en) | 2011-08-09 |
WO2008138854A1 (en) | 2008-11-20 |
MX2009011987A (es) | 2009-11-19 |
CA2686891A1 (en) | 2008-11-20 |
US20100217002A1 (en) | 2010-08-26 |
EP2158200B1 (en) | 2011-07-13 |
EP2158200A1 (en) | 2010-03-03 |
JP2010526122A (ja) | 2010-07-29 |
TW200904815A (en) | 2009-02-01 |
AU2008250348A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meltzer et al. | 2-Carbomethoxy-3-aryl-8-bicyclo [3.2. 1] octanes: potent non-nitrogen inhibitors of monoamine transporters | |
CA2582297A1 (en) | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
JPH07501074A (ja) | コカイン受容体結合性リガント | |
US7781456B2 (en) | Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors | |
CA2673454A1 (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
CN101679407B (zh) | 新的苯并吡喃-2-酮衍生物 | |
CN107445867A (zh) | 一种盐酸班布特罗杂质b的合成方法 | |
JP2006517567A (ja) | 新規8−アザ−ビシクロ[3.2.1]オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法 | |
EP1761527A1 (en) | Novel 9-aza-bicyclo¬3.3.1|nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
CA2570064A1 (en) | Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
Dutta et al. | Rational design and synthesis of novel 2, 5-disubstituted cis-and trans-piperidine derivatives exhibiting differential activity for the dopamine transporter | |
CN104829591B (zh) | 氘代匹莫齐特的制备方法 | |
BRPI0719578A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de uma doença ou um distúrbio ou uma condição de um corpo de animal vivo | |
Iorio et al. | Synthesis, stereochemistry, and biological activity of the 1-(1-phenyl-2-methylcyclohexyl) piperidines and the 1-(1-phenyl-4-methylcyclohexyl) piperidines. Absolute configuration of the potent trans-(-)-1-(1-phenyl-2-methylcyclohexyl) piperidine | |
CN103073510A (zh) | 一类吡嗪基新西弗碱化合物的结构、制备和用途 | |
US20100286195A1 (en) | Novel benzooxazol-and benzooxathiol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
JP2010539075A (ja) | フェノキサジン−3−オンの新規誘導体、並びにモノアミン神経伝達物質再取り込み阻害剤としてのその使用 | |
CN110669097A (zh) | 一种齐墩果烯衍生物的合成方法 | |
CN106866575A (zh) | 2‑(1‑哌啶基)‑5‑溴噻唑的合成方法 | |
TW202118519A (zh) | 多巴胺正子造影劑標幟前驅物芳香環硼氧衍生物之製造方法 | |
CN101267820A (zh) | 新颖氮杂双环[3.2.1]辛-2-烯衍生物及其作为单胺神经递质再摄取抑制剂的用途 | |
CA2592130A1 (en) | Novel naphthyl substituted azabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20130508 |